In 2009 the scientists of Eli Lilly, together with Amylin Pharmaceuticals had launched a revolutionary new brand of insulin product for patients with diabetes mellitus type 2. Currently, the drug is available in two forms:
You can buy these products on our website Insulin.Store at the most beneficial prices.
The remedy is a colorless and transparent solution for subcutaneous injections. The active substance in Byetta is exenatide.
Byetta is a hypoglycemic drug, glucagon-like peptide receptor agonist.
In terms of its structure, exenatide (the active substance in Byetta) is a synthetic peptide, 53% identical to human GLP-1. By interacting with the GLP-1 receptor in the pancreas and other organs and tissues, Exenatide reproduces all the effects of GLP-1:
Exenatide significantly increases both the 1st (0–10 min) and the 2nd (10–120 min) phases of insulin secretion. It is especially important that the insulinotropic effect of Byetta is glucose-dependent, i.e., it is realized only with an increased level of glycemia. This means that exenatide causes a dose-dependent increase in plasma insulin concentration as long as the increased glycemic level remains (in the experiment, within 3 hours after drug administration). Upon reaching normal glucose levels, the insulin concentration returns to the basal level. This mechanism of action of the drug helps to reduce the risk of hypoglycemia.
The effect of Byetta therapy, which was initially seen as complementary, is gaining momentum, especially in view of the catastrophic rise in overweight and obesity among diabetes mellitus type patients. This is a decrease in body weight that is observed in most patients almost from the very beginning of treatment with Byetta.
The mechanism of the effect of Byetta on body weight appears to be multifactorial and may be related to the central action of the drug, which helps reduce appetite and faster satiety.
It was found that the decrease in body weight on therapy with Byetta occurs precisely due to adipose tissue, mainly visceral fat, while lean body weight does not change. These data were obtained in a small study of 36 patients with T2DM in the study of body composition using dual-energy X-ray absorptiometry and were published in 2010.
Exenatide’s ability to reduce abdominal obesity undoubtedly requires further study. However, this property of the drug can become one of the powerful factors influencing the pathogenetic mechanisms of T2DM progression and cardiovascular risk.
The most common possible side effects of Byetta therapy were gastrointestinal disturbances:
Another side effect that may occur when taking Byetta is hypoglycemia (low blood sugar). Although the hypoglycemic effect of exenatide is glucose-dependent and does not affect the mechanism of physiological regulation of glucose in conditions of hypoglycemia, Byetta therapy is associated with a low risk of hypoglycemia.
As with any medication, the reaction of the organism to Byetta injections may vary. Monitor your blood sugar levels regularly and inform your doctor of any changes in your glucose level or health condition.
In addition to improving glycemic control and reducing body weight, in many studies during therapy with Byetta, an improvement in the profile of risk factors for cardiovascular risk was noted – a decrease in blood pressure and atherogenic lipid fractions, C-reactive protein, as well as an increase in adiponectin levels.
Thus, with long-term continuous therapy with Byetta (3.5 years), it was shown a decrease in total cholesterol by 5%, low-density lipoprotein (LDL) – by 6%, triglycerides – by 12%, and an increase in high-density lipoprotein (HDL) – by 24%.
It is very important to follow when and how to take Byetta to maximize your glycemic benefits. The optimal glucose-lowering effect is achieved when the drug is administered within an hour before a meal. The interval between morning and evening injections should be at least 6 hours so that the effect of the drug is evenly distributed throughout the day. The maximum effectiveness of therapy, both in terms of HbA1c and a decrease in body weight, is observed with a full dose of Byetta 10 μg 2 times a day. As with any other antihyperglycemic drug therapy, exenatide therapy is most effective when combined with a healthy lifestyle and diet.
The Byetta drug should be stored out of the reach of children, protected from light, not frozen, at a temperature of 2 ° to 8 ° C.
Shelf life is 3 years.
The drug in use in a syringe pen should be stored at a temperature not exceeding 25 ° C for no more than 30 days.
Any insulin-based medication according to the rules requires offline or online pharmacies store representatives to ask for a prescription. When buying Byetta from Insulin.Store, you will need to attach a valid prescription from the doctor for the insulin product even if you buy it for your pet. We will be able to proceed with your order just upon successful verification of your prescription. In the opposite case, we will have to either ask you to provide a valid prescription or cancel your order.
When your prescription expires, you will also have to attach a new prescription from your doctor. Read the ‘How to order’ page for more information.
Insulin Store, a Canadian pharmacy that specializes in insulin and insulin-like products and dietary supplements for adults, children, and even their pets with type 2 and type 1 diabetes mellitus, offers one of the best prices for Byetta:
Please note that the prices may vary. Visit our website Insulin.Store or contact our sales managers to check the current prices.
Insulin Store has extended the market of our trade, and now we ship to the USA. Why should you choose Insulin Store?
You can order Byetta or any other medication either on our website Insulin.Store or by contacting our sales managers. In both cases, you will have to create a personal account and provide a valid prescription for the drug.
If you have any questions, do not hesitate to dial our team, and we will try to help you out with all your concerns.